Form 8-K · Current Report · Filed 2024-01-29
Abbott Laboratories Enters New Five-Year Revolving Credit Agreement
On January 29, 2024, Abbott Laboratories entered into a new Five-Year Revolving Credit Agreement, providing the company with the ability to borrow up to $5 billion on an unsecured basis.
- Filer
- Abbott Laboratories ABT · NYSE
- Filed
- Accession
- 0001104659-24-007725
- CIK
- 0000001800
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
This agreement replaces an existing credit agreement, which was terminated on the same day. The new agreement will mature on the fifth anniversary of the effective date, and Abbott's borrowings will bear interest based on either a base rate or a SOFR rate, plus an applicable margin.
Items reported
Entry into a Material Definitive Agreement
Termination of a Material Definitive Agreement
Creation of a Direct Financial Obligation
Market reaction
Close before filing
$112.01
Next session
+1.3%
Since filing
-5.6%
Latest close
$105.70
What happened, not what will happen — closing prices around the filing date.
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Never miss another ABT filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.